How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? (Q35209086)

7 August 2017

1 reference

title

How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? (English)

1 reference

7 August 2017

Marc S Weinberg

1

1 reference

PubMed ID

12948435

7 August 2017

Nicholas Kaperonis

series ordinal

2

1 reference

PubMed ID

12948435

7 August 2017

George L Bakris

series ordinal

3

1 reference

7 August 2017

1 October 2003

1 reference

Current Hypertension Reports

7 August 2017

1 reference

7 August 2017

5

1 reference

7 August 2017

5

1 reference

7 August 2017

418-425

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-003-0088-8

7 August 2017

0 references

cites work

The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0088-8

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0088-8

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0088-8

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0088-8

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

12 December 2020

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

12 December 2020

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

12 December 2020

Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

12 December 2020

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide

1 reference

12 December 2020

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

12 December 2020

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

12 December 2020

Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial

1 reference

12 December 2020

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

12 December 2020

Treatment of hypertension in adults with diabetes

1 reference

12 December 2020

Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group

1 reference

12 December 2020

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects

1 reference

12 December 2020

Dual renin-angiotensin system blockade at optimal doses for proteinuria

1 reference

12 December 2020

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

12 December 2020

Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS).

1 reference

12 December 2020

Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels

1 reference

12 December 2020

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

12 December 2020

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

1 reference

12 December 2020

1 reference

12 December 2020

Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure

1 reference

12 December 2020

beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure

1 reference

12 December 2020

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril.

1 reference

12 December 2020

Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Titrating for antiproteinuric effect: the clue to renoprotection?

1 reference

12 December 2020

Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison

1 reference

12 December 2020

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i

1 reference

12 December 2020

Dosing angiotensin II blockers—beyond blood pressure

1 reference

12 December 2020

The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes

1 reference

12 December 2020

Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy

1 reference

12 December 2020

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study

1 reference

12 December 2020

Optimal dose of losartan for renoprotection in diabetic nephropathy

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Losartan titration versus diuretic combination in type 2 diabetic patients

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

The paradox of the low-renin state in diabetic nephropathy

1 reference

12 December 2020

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

12 December 2020

Renoprotective therapy: titration against urinary protein excretion

1 reference

12 December 2020

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

1 reference

12 December 2020

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

12 December 2020

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

1 reference

12 December 2020

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria

1 reference

12 December 2020

Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease

1 reference

12 December 2020

Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease

1 reference

12 December 2020

10.1007/S11906-003-0088-8

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12948435